Substitute	form 1449A/PTO			Complete if Known				
				Application Number	To Be Assigned 10/806, 523			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			E	Filing Date	Concurrently			
			Т	First Named Inventor	Nnochiri N. Ekwuribe			
OIX C	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	•	Group Art Unit				
(use as many sheets as necessary)				Examiner Name				
Sheet	1	of	1	Attorney Docket Number	9233-64CT			

			U.S. PATENTS	AND PATENT PUBLICATIONS	
Examiner Initials*	Cite No.	U.S. Patent		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		Number	Kind Code (if known)	Document	MM-DD-YYYY
kr	1	US-6,506,730	B1	Lee et al.	01/14/2003
<i>D</i>		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
	<u> </u>	US-			
		US-			
		US-			
	<u> </u>	US-			
	ļ	US-			
**		US-			
	ļ	US-			
		US-			1:
		US-	`		
	 	US-			
	<u> </u>	US-			
	<u> L</u>	US-	· .		

				FOREIGN PA	TENT DOCUMENTS		
Examiner Initials*	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication	T
muas	No.	Office	Number	Kind Code (if known)	Document	of Cited Document MM-DD-YYYY	
	 						
	 						
				_			
	ļ	ļļ		<u>-</u>			
	 	 	-				
	 	-					•
	 					 	
							

Examiner Signature	Jeffrey	E. Russel	Date Considered	June 16,2005
--------------------	---------	-----------	-----------------	--------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

								10/806,523
FORM PTO-1	449 U Patent	.S. Department o and Trademark C	f Commerce			cket Number 923.	T	Serial No09/873,777
LIST O	F DOC	JMENTS CITEI	BY APPLIC	ANT	42	.33-64C	• 1	1) Apiranto
RE	Ore	several sheets if n	ecessary)					(9,7
0	700 S				Applicants:			
The state of the s	N TOCAL TO)			Filing Date:	June 4, 2000 Oncurre	ently	Group
			U. S.	PATENT DO	CUMENTS			
Examiner Initial		Document Number	Date		Name	Class	Subclass	Filing Date if Appropriate
SR	1.	4,179,337	12/18/79	Davis et al.		435	181	
30	. 2.	5,359,030	10/25/94	Ekwuribe		530	303	
Tolland	3.	5,405,877	04/11/95	Greenwald et al.		514	772.3	·
182	4.	5,567,422	10/22/96	Greenwald		424	78.3	
182	5.	5,681,811	10/28/97	Ekwuribe		514	8 .	
					<u></u>	 	-	
			FOREIG	CNI DATENIT	DOCUMENTS	<u> </u>	<u></u>	
T			FOREI	GNFATENT	DOCUMENTS	1		Translation
		Document Number	Date	c	Country	Class	Subclass	Yes No
			<u> </u>			<u> </u>		
			<u> </u>		<u> </u>			
A . T	 -	r			r, Title, Date, P			
JR.	6.	Banting et al., 141-146 (1922		xtracts in the T	reatment of Dia	abetes Mellitu	ıs," Can. Med.	Assoc. J., 12:
XV	7.	H. Allcock &	F. Lampe, "Co	ntemporary Po	olymer Chemist	ry," 394-403	(2nd. ed., 199	1).
M	8.	Y. Chen & G. (1999).	Baker, "Synth	esis and Prope	rties of AMA A	mphiphiles,"	J. Org. Chem	., 64: 6870-6873
M.	9.	"Pharmaceutic 3(6): 318-326		Official Journa	al of the Americ	an Associatio	on of Pharmace	eutical Scientists,"
SR	10	Coudert et al., 16(1): 19-26 (equivocal Syn	thesis of Polyet	hylene Glyco	ls," Synthetic (Communications,
yr.	11	J. Milton Harr Rev. Macromo			Polyethylene G 5-373 (1985).	lycol Derivat	ives," <i>J. Macro</i>	omol. Science -

EXAMINER EXAMINER.

Jeffrey Elizze DATE CONSIDERED Febrey 11,2003/June 16,2005
Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	OF DOC	J.S. Department o and Trademark C UMENTS CITEI several sheets if n	BY APPLIC	ANT	Attorney Doci	yer RE	CEIVE 1 2002 ENTER 1600	A5516NED
					June 4, 2000	Concu	rently	1646
			U. S.	PATENT DO	CUMENTS		T - T	
Examiner Initial		Document Number	Date]	Name	Class	Subclass	Filing Date if Appropriate
D	1.	5,349,052	09/20/94	Delgado et a	al	530	351	
U								
		•	•					
					·		_	
			FOREIC	GN PATENT I	DOCUMENTS			
		Document Number	Date	С	ountry	Class	Subclass	Translation Yes No
XV.	2.	0 511 903 A2	11/04/92	EPO		C08G	65/32	X (Abstract)
yr	3.	WO97/14740	04/24/97	PCT	· · · · · · · · · · · · · · · · · · ·	C08G	65/32	x
		OTHER DOC	UMENTS (Inc	cluding Author	r, Title, Date, Per	tinent Pages	, Etc.)	
X1	4.	International Se	arch Report c	orresponding	to PCT/US02/17:	575; Date of	Mailing: Sep	tember 25, 2002.
U								
					1			

EXAMINER EXAMINER

Jeffer Elluse

DATE CONSIDERED

February 11.20

1.2003/ June 16,2005

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

stitute form 1449A/PTO Complete if Known 09/873,777 Application Number TO **INFORMATION DISCLOSURE** Filing Date June 4, 2001 STATEMENT BY APPLICANT ब्रोirst Named Inventor Ekwuribe Froup Art Unit 1654 Examiner Name Jeffrey E. Russel (use as many sheets as necessary) Attorney Docket Number Δ£ Sheet 9233.64 **PATENT DOCUMENTS** U.S. Patent Document Pages, Columns Lines, Where Relevant Passages or Relevant Figures Las Apparer Liber Examiner Cite No. Name of Patentee or Applicant Date of Publication of Initials* of Cited Document Cited Document Number Kind Code MM-DD-YYYY (if known) 4,223,163 Guilloty 09/16/1980 568/618 Pardridge 2 4,801,575 01/31/1989 514/4 3 5,099,074 Mueller et al. 03/24/1992 568/617 5,122,614 Zalipsky 06/16/1992 548/ Sao 5 5,298,410 Phillips et al. 03/29/1994 435/188 5,320,840 6 Camble et al. 06/14/1994 404/851 5,714,639 Bowman et al. 02/03/1998 S68/620 8 5,428,128 Mensi-Fattohi et al. 06/27/1995 530/302 5,468,478 Saifer et al. 11/21/1995 424 78,27 5,612,460 10 Zalipsky 03/18/1997 530/3919 11 5,637,749 Greenwald 06/10/1997 558/6 5,643,575 12 Martinez et al. 07/01/1997 424/1941 5,854,208 13 Jones et al. 12/29/1998 514/3 6,011,008 Domb et al. 01/04/2000 514/8 FOREIGN PATENT DOCUMENTS Examiner Cite Foreign Patent Document Name of Patentee or Date of Publication Pages, Columns, Lines, Initials* No. Applicant of Cited of Cited Document Office Number Kind Code Passages or Relevant **Document** MM-DD-YYYY (if known) 15 DE 196 32 440 A1 **BASF AG** 02/19/1998 16 EP 0 822 218 A2 Glenn A. Miller, 02/04/1998 Michael W. Jorgenson. Richard Budnik 17 JP 01207320 Daicel Chem Ind Ltd. 08/21/1989 (Abstract Only) 18 WO 01/12230 PCT Myung-Ok Park, Kang 02/22/2001 Choon Lee OTHER NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, Examiner Cite serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials* No. Francis, G.E., et al., Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour 19

<u> </u>		·				•		
Examiner Signature	Jeffre-	, E. Russel	_	Date (Considere	d	July 9	2003 June 16, 2005

Guzman, Angel, et al., Effects of Fatty Ethers and Steanc Acid of the Gastrointestinal Absorption of

Targeting, Journal of Drug Targeting, Vol. 3, pp. 321-40 (1996)

Insulin, PRHSJ, Vol. 9, No. 2, pp. 155-159 (August 1990)

20

Complete if Known ostitute form 1449A/PTO 09/873,777 TO BE Application Number INFORMATION DISCLOSURE Filing Date June 4, 2001 CONE First Named Inventor Ekwuribe STATEMENT BY APPLICANT Group Art Unit 1654 Jeffrey E. Russel **Examiner Name** (use as many sheets as necessary) 9233.64 Sheet **Attorney Docket Number** OTHER NON PATENT LITERATURE DOCUMENTS Krishnan, B. Radha, et al., Stability and Physical Characteristics of Orally Active Amphiphilic Human Insulin Analog, Methoxy (Polyethylene Glycol) Hexanoyl Human Recombinant Insulin (HIM2), Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., Vol. 27 pp. 1038-39 (2000) Lindsay, D.G., et al., The Acetylation of Insulin, Biochem J., Vol. 121, pp. 737-745 (1971) Mesiha, M.S., et al., Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 23 and stearic acid, J. Pharm. Pharmacol., Vol. 33, pp. 733-34 (1981) Moghaddam, Amir, Use of polyethylene glycol polymers for bioconjugations and drug development, American Biotechnology Laboratory, pp. 42, 44 (July 2001) 25 Neubauer, H. Paul, et al., Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals, Diabetes, Vol. 32, pp. 953-58 (October 1983) Shen, Wei-Chiang, et al., (C) Means to Enhance Penetration; (3) Enhancement of polypeptide and 26 protein absorption by macromolecular carriers via endocytosis and transcytosis, Advanced Drug Delivery Reviews, Vol. 8, pp. 93-113 (1992) Sirokman, Geza, et al., Refolding and proton pumping activity of a polyethylene glycolbacteriorhodopsin water-soluble conjugate, Protein Science, Vol. 2, pp. 1161-1170 (1993) Torchilin, Vladimir P., Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents, Immunomethods, Vol. 4, pp. 244-58 (1994) Wei, Jiang, et al., A Poly(Ethylene Glycol) Water-soluble Conjugate of Porin; Refolding to the Native 29 State, Biochemistry, Vol. 34, pp. 6408-6415 (1995) Xia, Jiding, et al., Effects of polyoxyethylene chain length distribution on the interfacial properties of polyethylene glycol n-dodecyl ether, Yingyong Huaxue, Vol. 2, No. 4, pp. 59-65 (Abstract Only) (1985) Zalipsky, Samuel, et al., Peptide Atlachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR, Bioconjugate Chem., Vol. 6, pp. 705-8 (1995)

Examiner Signature Jeffrey E. N. Jecl Date Considered July 9. 2003/Jun 16, 2003

C mplet if Knowl Substitute form 1449APTC 09/079 704 Application Number INFORMATION DISCLOSUREO Filing Date First Named Inventor 06/04/2901 Concis Nnochirl N. Ekwuribe STATEMENT BY APPLICANT **Group Art Unit** 1711 Examiner Name Ouc Truong Attorney Docket Number 9233- 64CT


			U.S. PATE	NTS AND PATENT PUBLICATION		Class/Subclass		
Examiner	Cite No.	U.S. Palent C	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Linea. Where Relevant Passages		
initials*		Number	Kind Code (if known)	Of Criso Document	MM-DD-YYYY	or Relevant Rigures		
XIV	1	2003/0144468	A1	Ekwuribe et al.	07/31/2003	588 / 425		
7 WW	2	2003/0087808	A1	Soltero et al.	05/08/2003	514/3		
47	3	2003/0083232	A1	Soltero et al.	05/01/2003	514 13		
XV	/ 4 _	2003/0089170	A1	Soltero et al.	04/10/2003	514/2		
XIL	5	2003/0050228	A1	Ekwuribe et al.	03/13/2003	517/3		
(1/2/)	/ 6	2003/0027995	A1	Ekwuribe et al.	02/06/2003	530/399		
XX	77	2003/0027748	A1	Ekwuribe et al.	02/06/2003	SM 3		
XIV		2003/0004304	A1	Ekwuribe et al.	01/02/2003	528/425		
USIN	9	8,323,311	B1	Liu et al.	11/27/2001	530 303		
Ter	10	6,191,105		Ekwuribe et al.	02/20/2001	514/3		
23/	111	6,057,292		Cunningham et al.	05/02/2000	514 la		
	12	5,597,797		Clark	01/28/1997	517/12		

	FOREIGN PATENT DOCUMENTS											
Examiner Cits No.		F	oreign Patent Doc	ument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	٦				
	No.	Office	Number	Kind Code (if known)		MM-DD-YYYY						
	├	 						╁╴				
	<u> </u>							↓_				
•	1	1 1				<u></u>	l					

Examiner Initials*	or Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jour No. serial, symposium, catalog, etc.), date, page(a), volume-lasue number(s), publisher, city and/or country where published						
RN	13	Still et al., Methods of Reducing Hypoglycemic Episodes in the Treatment of Diabetes Methus, U.S. Serial No. 10/461,199, filed 06/13/2003					
MI	14	Radhakrishnan et al., Insulin Polypeptide-Oligomer Conjugates, Proinsulin Polypeptide-Oligomer Conjugates and Methods of Synthesizing Same, U.S. Serial No. 10/389,499, filed 03/17/2003					
Ju	15	Soltero et al., Pharmaceutical Compositions of Insulin Drug-Oligomer Conjugates and Methods of Treating Diseases Therewith, U.S. Serial No. 10/382,155, filed 03/05/2003					
An	16	Soltero et al., Pharmaceutical Compositions of Drug-Oligomer Conjugates and Methods of Treating Diseases Therewith, U.S. Serial No. 10/382,069, filed 03/05/2003					
Ser.	17	Soltero et al., Insulin Polypeptide-Oligomer Conjugates, Proinsulin Polypeptide-Oligomer Conjugates and Methods of Synthesizing Same, U.S. Serial No. 10/382,022, filed 03/05/2003	-				
m	18	Ekwuribe et al., Calcitonin Drug-Oligomer Conjugates, and Uses Thereof, U.S. Serial No. 10/166,355, filed 11/08/2002, including Preliminary Amendment dated 02/26/2003 and Supplemental Preliminary Amendment dated 03/31/2003					
M	19	Ekwuribe et al., Mixtures of Drug-Oligomer Conjugates Comprising Polyalkylene Glycol, Uses Thereof, and Methods of Making Same, U.S. Serial No. 09/873,797, filed 06/04/2001					
kr	20	Ekwuribe et al., Hydrophilic and Lipophilic Balanced Microemulsion Formulations of Free-Form and/or Conjugation-Stabilized Therapeutic Agents Such as Insulin, U.S. Serial No. 09/614,203, filed 07/12/2000					
AZV	21	Hinds et al., Synthesis and Characterization of Poly9ethylene glycol)-Insulin, Bioconjugate Chem., Vol. 11, 2000, pp. 195-201					
Uster	. 22	Ekwuribe et al., Amphiphilic Prodrugs, U.S. Serlal No. 09/474,915, filed 12/31/1999					

				/\	
Examiner Signature	- 66		Date Considered	1 2 - 1	_
CADMINICI OIGNOLUIC		D. cs Sal	04.0 001.000.00	1 /2003/ Char	IL NAME
	1000000	MUSSEL		Decensión y Journe	2002
ACMANANCO, INTO THE	4		THE MICE CO.	Described through district M	•

PECO



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

Title of Invention

MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME

Application Number:

09/873777 TO BE ASSIGNED

Confirmation Number:

2316

First Named Applicant:

Nnochiri Ekwuribe

Attorney Docket Number: 9233.64

Art Unit:

1654

Examiner:

Jeffrey E. Russel

Search string:

(3256153 or 3868356 or 3919411 or 3950517 or 4003792 or 4044196 or 4087390 or 4093574 or 4100117 or 4229438 or 4253998 or 4277394 or 4338306 or 4348387 or 4410547 or 4469681 or 4554101 or 4579730 or 4585754 or 4662392 or 4684524 or 4698264 or 4717566 or 4774976 or 4772471 or 4797288 or 4839341 or 4840799 or 4849405 or 4917888 or 4935246 or 4946828 or 4957910 or 4963367 or 4963526 or 5013556 or 5055300 or 5055304 or 5089261 or 5093198

or 5206219 or 5286637 or 5283236 or 5292802 or 4472382 or 4994439 or 20020160938 or 20030144468 or 20030087808 or 20030083232

or 5157021 or 5162430 or 5164366 or 5202415

or 20030069170 or 20030050228 or 20030027995 or 20030027748 or

20030004304).pn.

RECEIVED
TECH CENTER 1600/2900

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
RA	- 1	3256153	1966-06-14	Heimlech		424	/ 497
M	2-	3868356	1975-02-25	Smyth		536	303
应	3	3919411	1975-11-11	Glass et al.		424	78,27
M		3950517	1976-04-13	Lindsay et al.		5141	3
厕	_ 5	4003792	1977-01-18	Mill et al.	7	530 l	303

APP_ID=09873777

Jeffrey E. ausel

December 30,2003/ June 16, 2005

	0				
٤	WILL WILL	6	4044196	1977-08-23	Huper et al.
	W/	7	4087390	1978-05-02	Shields
		8	4093574	1978-06-06	Shields
	94	9	4100117	1978-07-11	Shields
	M	10	4229438	1980-10-21	Fujino et al.
	网	11	4253998	1981-03-03	Sarantakis
	W/	12	4277394	1981-07-07	Fujino et al.
	W/	13	4338306	1982-07-06	Kitao et al.
	224	14	4348387	1982-09-07	Brownlee et al.
		/ · 15	4410547	1983-10-13	Ueno et al.
	92	16	4469681	1984-09-04	Brownlee et al.
	RU	17	4554101	1985-11-19	Норр
	XXI	18	4579730	1986-04-01	Kidron et al.
	M	19	4585754	1986-04-29	Meisner et al
		20	4662392		Kdasz Meny otak
	RU	21	4684524	1987-08-04	Eckenhoff et al.
	SIL	22	4698264	1987-10-06	Steinke
	881	23	4717566	1988-01-05	Eckenhoff et al.
	2	24	4774976	1988-	Tanecke et al.
		25	4772471	1988-09-20	Vanlerberghe et al.
	M	26	4797288	1989-01-10	Sharma et al.
	()	27	4839341	1989-06-13	Massey et al.
	M	28	4840799	1989-06-20	Appa Malacey et al.
	800	29	4849405	1989-07-18	Ecanow
		30 ·	4917888	1990-04-17	Katre et al.
	M	31	4935246	1990-06-19	Ahrens
	M.	32	4946828	1990-08-07	, Markussen
		33	4957910	1990-09-18	Sutton et al.
	2"	34	4963367	1990-10-16	Ecanow
	Zw.	35	4963526	1990-10-16	Ecanow
	73/4	- 36	5013556	1991-05-07	Woodle et al.
		37	5055300	1991-10-08	Gupta
		38	5055304	1991-10-08	Makino et al.
	250	39	5089261	1992-02-18	Nitecki et al.
	M	- 40	5093198	1992-03-03	Speaker et al.
		_ 41	5157021	1992-10-02	Balschmidt et al.

526/271 525/54.11 Sas /54.11 525/54.11 514/15 525/54.11 536 330 51414 517/4 514/557 517 4. 514/2 RECEIVE 514/3. 514/8 137 533.11 42414 TECH CENTER 1600/2900 428/402.2 424/438 137/14 424/450 424/476 514/4 424/493 514/3 424/85.91 424/490 51413 514/182 724/485 514/3 424/450 424/409 424/465 424/85.2

428/402,21 514/3

10/806,523

PL 42	5162430	1992-11-10	Rhee et al.	525/54.1
YM 43	5164366	1992-11-17	Balschmidt et al.	514/3
44	5202415	1993-04-13	Jonassen et al.	530 303
AN 45	5206219	1993-04-27	Desai	514 3
46	5286637	1994-02-15	Veronese et al.	435/183
47	5283236	1994-02-01	Chiou	514 12
48	5292802	1994-03-08	Rhee et al.	525/541
49	4472382	1984-09-18	Labrie et al.	514/15
50	4994439	1991-02-19	Longenecker et al.	514/3

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass	1
M	/ 1	20020160938	2002-10-31	Brandenburg et al.		514R	ECEIVE	
MAN AND AND AND AND AND AND AND AND AND A	2	20030144468	2003-07-31	Ekwuribe et al.)	528	425	
	- 3	20030087808	2003-05-08	Soltero et al.		SIY B	EC E 9 200	*
网	4	20030083232	2003-05-01	Soltero et al.		514	3	hoor
W	5	20030069170	2003-04-10	Soltero et al.	15112	TECH	CENTER 1600	1890c
M	6	20030050228	2003-03-13	Ekwuribe et al.		SIZ	3	
M	7	20030027995	2003-01-02	Ekwuribe et al.		530	399	
M	✓ · 8	20030027748	2003-02-06	Ekwuribe et al.		517	3	
X	9	20030004304	2003-01-02	Ekwuribe et al.		528	425	

Signature

Examiner Name	1	Date		
Jeffrey E. Russel		December 30,2003 /	Une 16	, 2005
		7		ľ

Page 3 of 3



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL. USES THEREOF, AND METHODS OF MAKING SAME

Application Number:

TO BE ASSIGNED -09/073777

Confirmation Number:

2316

First Named Applicant:

Nnochiri Ekwuribe

Attorney Docket Number: 9233.64

Art Unit:

1654

Examiner:

Jeffrey E. Russel

Search string:

(5304473 or 5308889 or 5312808 or 5324775 or 5328955 or 5405621 or 5413791 or 5415872 or 5438040 or 5444041 or 5446091 or 5457066 or 5461031 or 5504188 or 5506203 or 5518998 or 5523348 or 5529915 or 5545618 or 5550188 or 5597797 or 5606038 or 5631347 or 5646242 or 5650388 or 5658878 or 5681567 or 5693609 or 5693769 or 5700904 or 5707648 or 5738846

or 5747445 or 5747642 or 5750497 or 5763396 or 5766620 or 5824638 or 5830853 or 5830918 or 5843866 or 5849860 or 5853748 or 5856451 or 5866538 or 5866584 or 5874111 or 5898028

or 5902588 or 5905140).pn.

RECEIVED

TECH CENTER 1600/\$900

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind Class Subclass
RA	1	5304473	1994-04-19	Belagaje et al.	435/69.7
1994	2	5308889	1994-05-03	Rhee et al.	523/113
M	3	5312808	1994-05-17	Shorr et al.	514/6
MY	4	5324775	1994-06-28	Rhee et al.	525/54,a
MU	5	5328955	1994-07-12	Rhee et al.	525/54,1
M	6	5405621	1995-04-11	Sipos	424/490
XI	, 7	5413791	1995-05-09	Rhee et al.	424/422
M	. 8	5415872	1995-05-16	Sipos	424/490

APP_ID=09873777 Jeffrey E. Russe December 30, 2003 June 16, 2005

J.P.E	70.1
1	
XA.	. NEW 1821

Ĭ			,	N	
"RE	9	5438040	1995-08-01	Ekwuribe	517/3
MI	10	5444041	1995-08-22	Owen et al.	314/2
me	11	5446091	1995-08-29	Rhee et al.	525/541
THE	12	5457066	1995-10-10	. Frank et al.	435/68.1
MA	13	5461031	1995-10-24	De Felippis	514 4
MY	14	. 5504188	1996-04-02	Baker et al.	530/304i
FALF	15	5506203	1996-04-09	Backstrom et al.] s14 <i>)</i> 4
my	16	5518998	1996-05-21	Backstrom et al.	514/3
The last	17	5523348	1996-06-04	Rhee et al.	525/541
The	18	5529915	1996-06-25	Phillips et al.	435/188
764	19	5545618	1996-08-13	Buckley et al.] 514/1a
Re	20	5550188	1996-08-27	Rhee et al.	2 3-5 54.1
NO F	21	5597797	1997-01-28	Clark 2	514/12
SAU	22	5606038	1997-02-25	Regen	536/6.5
Sil	23	5631347	1997-05-20	Baker et al.	S30)363 RECEIVED
PFR	24	5646242	1997-07-08	Baker et al.	530/303
Free	25	5650388	1997-07-22	Shorr et al:	S14/6 BEE 1 9 2003
ME	26	5658878	1997-08-19	Backstrom et al.	SIMIS TECH CENTED 1600/2000
XY	27	5681567	1997-10-28	Baker et al.	31913 429 178 TECH CENTER 1600/2900
P1/2	28	5693609	1997-12-02	Baker et al.	3
BAL	29	5693769	1997-12-02	Kahne et al.	536/5
BUE	30	5700904	1997-12-23	Baker et al.	530)305
MAL	31	5707648	1998-01-13	Yiv	424/450
BAY.	32	5738846	1998-04-14	Greenwald et al.	424/85.7
85A	33	5747445	1998-05-05	Backstrom et al.	514)4
94E	34	5747642	1998-05-05	De Felippis	530 304
1504	35	5750497	1998-05-12	Havelund et al.	514/3
MUL	36	5763396	1998-06-09	Weiner et al.	514/3
ONE	37	5766620	1998-06-16	Heiber et al.] 424/436 .
BULL	38	5824638	1998-10-20	Burnside et al.	514/3
32	39	5830853	1998-11-03	Backstrom et al.	514/4
M	40 ·	5830918	1998-11-03	Sportsman et al.	514/648
X	41	5843866	1998-12-01	Park Wainer et al.	504/116
374	42	5849860	1998-12-15	Hakimi et al.	528/370
Ju.	43	5853748	1998-12-29	New	424/439
DVE	44	5856451	1999-01-05	Olsen et al.	530/402
		·)

APP_ID=09873777 Jeffrey B. Russel

December 30, 2003/June 1

	7					
	PPU	45	5866538	1999-02-02	Norup et al.	j.
	XYU.	- 46	5866584	1999-02-02	Cincotta et al.]
ļ	M	47	5874111	1999-02-23	Maitra et al.]
	舰	48	· 5898028	1999-04-27	Jensen et al.]
	XX	49	5902588	1999-05-11	Greenwald et al.]
	钇	5 0	5905140	1999-05-18	Hansen]

514/3 514/288 424/499 514/4 424/278,1 530/303


Signature

Jeffrey G. Russel December 30, 2003 / June 16, 2005	Examiner, Name	Date	
	Jeffrey G. Russel	December 30, 2003 / June 1.	,2005

RECEIVED

DEC-1 8 2003

TECH CENTER 1600/2900



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME

Application Number:

89/873777 TO BE ASSIGNED

Confirmation Number:

2316

First Named Applicant:

Nnochiri Ekwuribe

Art Unit:

Attorney Docket Number: 9233.64 1654

Examiner:

Jeffrey E. Russel

Search string:

(5907030 or 5922675 or 5932462 or 5942248 or 5948751 or 5952008 or 5952297 or 5962267 or 5968549 or 5969040 or 5981709 or 5985263 or 6004574 or 6025325 or 6034054 or 6042822 or 6043214 or 6051551 or 6057292 or 6063761 or 6093391 or 6113906 or 6165976 or 6177087 or 6191105 or 6200602 or 6211144 or 6248363 or 6251856 or 6258377 or 6268335 or 6306440 or 6309633 or 6310038 or 6323311 or 6335316

or 6342225).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
352	1	5907030	1999-05-25	Shen et al.] .	530/3	3(
per	2	5922675	1999-07-13	Baker et al.] :	51414	
XP.	3	5932462	1999-08-03	Harris et al.]	1351.188	1
XI	4	5942248	1999-08-24	Barnwell] 4	124/457	
Re	5	5948751	1999-09-07	Kimer et al.]	514/4	
742	6	5952008	1999-09-14	Backstrom et al.] '	424/4°	19
Pe	7	5952297	1999-09-14	De Felippis et al.]	514/3	į.
SKN	8	5962267	1999-10-05	Shin et al.]	425/6	,
RI	9	5968549	1999-10-19	New et al.]	42414	50
The	10	5969040	1999-10-19	Hallahan et al.]	525/	54.1

APP_ID=09873777 Jeffrey E. Russe

December 30,2003/

٥ī	·					•
1	R/L	11 .	5981709	1999-11-09	Greenwald et al.	
l	M	12	5985263	1999-11-16	Lee et al.	
	84V	13	6004574	1999-12-21	Backstrom et al.	
1	944	14	6025325	2000-02-15	Campfield et al.	
	M	15	6034054	2000-03-07	De Felippis et al.]
	WU	16	6042822	2000-03-28	Gilbert et al.]
	阳	17	6043214	2000-03-28	Jensen et al.]
	观	18	6051551	2000-04-18	Hughes et al.]
ı	W.	19	6057292	2000-05-02	Cunningham et al.]
	Z	≥ 20	6063761	2000-05-16	Jones et al.	5 1
	782	21	6093391	2000-07-25	Kabanov et al.	42
1	m	22	6113906	2000-09-05	Greenwald et al.	424
	PN	23	6165976	2000-12-26	Backstrom et al.	514
	M	24	6177087	2001-01-23	Greenwald et al.	42
	77	25	6191105	2001-02-20	Ekwuribe et al.	5
	M	26	6200602	2001-03-13	Watts et al.	۱
	M	27	6211144	2001-04-03	Havelund _	
	M	28	6248363	2001-06-19	Patel et al.	۱ ۹
l	M	29	6251856	2001-06-26	Markussen et al.	
١		30	6258377	2001-07-10	New et al.	<u> </u>
	M	31	6268335	2001-07-31	Brader	
	74	32	6306440	2001-10-23	Backstrom et al.]
1	M	33	6309633	2001-10-30	Ekwuribe et al.	
	M	34	6310038	2001-10-30	Havelund	
	712	35	6323311	2001-11-27	Liu et al.]
	22	36	6335316	2002-01-01	Hughes et al.	
		. 37	6342225	2002-01-29	Jones et al.	<u> </u>

530/351
424/85.2
4241434
514/2
514/4
424/85.7
514/3
51413
514/12
. ^

51411-51413 424185.1 241814.1 1413 TECH CENTER 1600,000 4241218.1 51413 4241463

514/4
424/497
514/3
424/490
514/3
424/85,1
514/4
530/303

424/1931

Signature

Examiner Name	Date	
Jeffrez E. Russel	December 30, 2003/June 16,	2005

10/806,593 Applasts	(* / *)
	== <i>"</i>

FURM PTO-1449 U.S. Department of Commerce Patent and Trademark Office			Attorney Doo	ket Number 9233-64 <i>C</i> T		PETO BE E		
LIST OF DOCUMENTS CITED BY APPLICANT					TECHO	ALSIGNE MASIGNE		
	. (Use several sheets i	f necessary	E \				WIER ICO
			يبعدوه	CC B	Applicants:	Ekwur	ibe et al.	1600/2900
		•	PRE	St. St. St.	Filing Date Lune 4 , 2001	- Concu	erently	Group 1654
			FORE	IGN PATENT	DOCUMENTS			
		Document Number	Date	Co	untry	Class	Subclass	Translation Yes No
ARC	1.	GB 1 492 997	11/23/77	Great Britain				
45/	2.	EP 0 031 567	07/08/81	EPO	٠,			
XYV	3.	JP 1 254 699	10/11/89	Japan				·
YV	4.	0483465B1	05/06/92	EPO		_		
XV	5.	WO93/01802	02/04/93	PCT				
AN	6.	WO95/09831	04/13/95	PCT	-			
XX	7.	EP 0 483 465	08/02/95	EP				
1/2/	8.	WO95/30641	11/16/95	РСТ				·
WAC	9.	EP 0 597 007	10/16/96	EP				
XI	10.	EP 0 621 777	11/09/96	EP ·		<u> </u>		
SAL	11.	EP0797615B1	01/10/97	EPO				
MI	12.	WO98/07745	02/26/98	PCT				
KL	13.	WO99/32134	07/01/99	PCT				
MI	14.	WO99/65941	12/23/99	PCT				•
V		OTHER DO	CUMENTS (I	ncluding Autho	or, Title, Date, Po	ertinent Pages	s, Etc.)	
RN	15.	Holcenberg, John	Wiley (1981)					es as Drugs, Ed. J. S
M	16.	Agarwal et al. "Po Vitro Dissolution 225:31-39 (2001)						
XI	17.	Akiyama et al. "The Synthesis of New Derivatives of 1-\(\beta\)-D-Arabinofuranosylcytosine" Chem. Pharm. Bull. 26(3):981-984 (1978)						
1×1	18.	Allaudeen et al. "	Orally Active	_				idies" 60th Annual
Mer.	19.	Anderson et al. "H	Meeting of the American Diabetes Assoc., Atlanta, GA, June 2000 (Abstract) Anderson et al. "HIM2, a Novel Modified Insulin, has Improved Systemic Pharmacokinetics in Normal Dogs, Compared to Unmodified Insulin" American Diabetes Association 62nd Annual Meeting, June 2002 (Abstract)					
M	20. Ansell et al. "Application of Oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations" Bioconjugate Chem. 10:653-666 (1999)							
- 1/.								

EXAMINER *EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office			Attorney Docket Number 9233-64CT	Serial No. -89/873,777
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				TO BE IASSIGNED.
(Use several sheets if necessary)			Applicants: Ekwuribe et al.	
		PADEMARY CO	Filing Date Jume 4, 2001 CONCURRENTLY	Group 1654
An	21	Aoshima et al. "N ⁴ -Behenoyl-1-β-D-Arabinoft Research 37:2481-2486 (1977)		750
XX	22	Baker, D. C. et al. "Prodrugs of 9-\u03b3-D-Arabino Acyl) Derivatives" J. Med. Chem. 21(12):1218	furanosyladenine. 1. Synthesis and Evaluat -1221 (1978)	ion of Some
M	23	Banting et al. "Pancreatic Extracts in the Treats Assoc. J. 145(10):1281-1286 (1991)	ment of Diabetes Mellitus: Preliminary	port" Can. Med.
XI	24	Baudys et al. "Stabilization and Intestinal Absorption		
92/	25	Baudys et al. "Synthesis and Characterization of Symp. Cont. Rel. Bioactive. Mater. 19:210-211		sulin" <i>ProceOG Interr</i>
XX	26	Block, Lawrence H. "Pharmaceutical Emulsion	ns and Microemulsions" Pharmaceutical De	osage Forms:
XX	Disperse Systems Vol. 2, Ed. Lieberman et al., pp.47-109 (1996) Boccu et al. "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase" Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase" Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase Pharmacokinetic Properties Of Polyethylene Pharmacokinetic Properties Of Po			Dismutase" <i>Pharm</i> .
AL	Res. Comm. 14:113-120 (1982) Bone et al. "Successful Treatment of an Insulin Dependent Rat Model of Human Type I Diabetes with Orally Active Insulin" Program and Abstracts, 4th International Workshop on Lessons from Animal Diabetes, Omiy Japan, November 1994 (Abstract)			piabetes with Orally mal Diabetes, Omiya,
M	Bone et al. "Successful Treatment of Type 1 Diabetes with Orally-Active Insulin: Studies in The Insulin Dependent BB/S Rat" Program and Abstracts, 55th Annual Meeting of the American Diabetes Association, Atlanta Georgia, June 1995 (Abstract)			in The Insulin petes Association,
m	30 Brange and Volund "Insulin Analogs with Improved Pharmacokinetic Profiles" Advanced Drug Delivery Reviews 35:307-335 (1999)			Drug Delivery
XI	31.	Brange et al. "Chemical Stability of Insulin. 1. Preparations" <i>Pharm. Res.</i> 9(6):715-726 (1992)		Pharmaceutical
XI	32.	Brange et al. "Chemical Stability of Insulin. 2. During Storage of Pharmaceutical Preparations	Formation of Higher Molecular Weight Tra	ansformation Product
XX	33.	Daniel The Dhusian (Chemical and Pharmaceutical Aspects of In-	sulin and Insulin
XV	34.			k, N.Y. (1992)
M	35.	Cleland et al. "Emerging Protein Delivery Met		
	Clement et al. "Effects of Multiple Doses of Orally Administered Hexyl Insulin M2 (HIM2) on Postprandial Blood Glucose (PPG) Concentrations in Type 1 Diabetic (T1) Patients" American Diabetes Association 62n Annual Meeting, June 2002 (Poster)			
VARI	37	Clement et al. "Oral Insulin Product Hexyl-Ins Glucose Stabilization Effects of HIM2" Diabe.		
M	38.	Clement, Stephen "A Dose-Escalation Study of Insulin on Blood Glucose Concentrations in Pa Association Annual Meeting (June 25, 2001) (f the Effects of Two Sequential Doses of Oratients with Type 1 Diabetes Mellitus" Ame	ral Modified
XX.	Association Annual Meeting (June 25, 2001) (Abstract) Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (June 25, 2001) (Poster)			

EXAMINER *EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Db/806,523

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket Number 9233-64CT	Serial No.	
LIST OF DOCUMENTS CITED BY APPLICANT		TO BE ASSIGNED	
(Use several sheets if necessary)	Applicants: Ekwuribe et al.	Grown Grown	
TRANFAAR PART	Filing Date June 4, 2001 CONCURRALTO	Group Cc1654	
40 Conradi et al. "The Influence of Peptide Struct 8(12):1453-1459 (1991)	ture on Transport Across Caco-2 Cells" Pho	urm. Kest.Ep 1600	
41 Coombes et al. "Biodegradable Polymeric Mic Surface Attachment of Hydrophilic Species Us Segments" <i>Biomaterials</i> 18:1153-1161 (1997)	sing the Concept of Poly(Ethylene Glycol)		
Damge et al. "Poly(alkyl cyanoacrylate) Nanos Pharmaceutical Sciences 86(12):1403-1409 (1		Journal of	
Dandona et al. "Effect of an Oral Modified Insulin on Blood Glucose Levels in Fasting and Fed Type 1 Diabetic Patients Receiving a 'Basal' Regimen of Injected Insulin" American Diabetes Association Annual Meeting (June 25, 2001) (Abstract)			
Delgado et al. "The Uses and Properties of PE Carrier Systems 9(3,4):249-304 (1992)	G-Linked Proteins" Critical Reviews in The	rapeutic Drug	
	Ekwuribe et al. Calcitonin Drug-Oligomer Conjugates, and Uses Thereof, U.S. Serial No. 10/166,355, filed 11/08/2002, including Preliminary Amendment dated 02/26/2003 and Supplemental Preliminary		
	Ekwuribe et al. Mixtures of Drug-Oligomer Conjugates Comprising Polyalkylene Glycol, Uses Thereof, and Methods of Making Same, U.S. Serial No. 09/873,797, filed 06/04/2001		
	Ekwuribe, Nnochiri "Conjugation-Stabilized Polypeptide Compositions, Therapeutic Delivery and Diagnostic Formulations Comprising Same, and Method of Making and Using the Same" Biotechnology		
48 Engel et al. "Insulin: Intestinal Absorption as V	Water-in-Oil-in-Water Emulsions" Nature 2	19:856-857 (1968)	
Fasano, Alessio "Innovative strategies for the (1998)	oral delivery of drugs and peptides" TIBTE	CH 16:152-157	
50 Forst et al. "New Aspects on Biological Activi Diabetes 106:270-276 (1998)	ty of C-peptide in IDDM Patients" Exp. Cli	n. Endocrinol.	
51 Gish et al. "Nucleic Acids. 11. Synthesis of 5'- Antileukemic and Immunosuppressive Activity		Possessing	
52 Gombotz & Pettit "Biodegradable Polymers for 6:332-351 (1995)	Gombotz & Pettit "Biodegradable Polymers for Protein and Peptide Drug Delivery" Bioconjugate Chem.		
Hashimoto et al. "Synthesis of Palmitoyl Deriv Pharmaceutical Research 6(2):171-176 (1989)		vities"	
Hinds et al. "Synthesis and Characterization of Chem. 11:195-201 (2000)	f Poly(ethylene glycol)-Insulin Conjugates"	Bioconjugate	
Hong et al. "Nucleoside Conjugates. 7. Synthe Conjugates of Ether Lipids" J. Med. Chem. 29		ofuranosylcytosine	
Hostetler et al. "Synthesis and Antiretroviral A Antiviral Nucleosides" The Journal of Biologic	ctivity of Phospholipid Analogs of Azidoth	ymidine and Other	
57 Igarashi et al. "Biologically Active Peptides Cont. Rel. Bioactiv. Mater. 17:367-368 (1990)	onjugated with Lecithin for DDS" Proceed.	Intern. Symp.	
Kemmler et al. "On the Nature and Subcellular Federation Proceedings 30(Abstract 924):121	Localization of the Proinsulin Converting	Enzymes"	

EXAMINER *EXAMINER

Teffic E. Russel

DATE CONSIDERED January 8, 2004/June 16,2005

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary) Applicants: Ekwuribe et al. Filing Date June Jun		U.S. Department of Commerce stent and Trademark Office	Attorney Docket Number 9233-64 CT	Serial No. 09/873,77 7
Applicants: Ekwuribe et al. Ekwuribe et al. Ekwuribe et al. Filing Date June 12001 (Concurse 11 1554) Kemmler et al. "Studies on the Conversion of Proinsulin to Insulin: 1. Conversion in Vitro with Trypsing Carboxyneptidases" The Journal of Biological Chemistry 246(22)/6786-6791 (1971) King et al. "The praparation of Protein Conjugates with Alkoxynolyethylene Glycols" Int. J. Peptide Protein Res. 16:147-155 (1980) Kipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) (Epients with Type 2 Diabetes "Emerging Treatments and Technologies 26:2 (2003) Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Pathwith Type 2 Diabetes "Hilling" American Diabetes Association Annual Meeting (June 2011) (Poster) with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 2011) (Abstract) Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" Genomics and Proteomics (Sept. 2002) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabeties Insulin" J. Clin. Invest. 77:717-723 (1986) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabeties Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) Marchutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation in Vitro" Biomaterials 21:1499-1507 (2000) Marchutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation in Vitro" Biomaterials 21:1499-1507 (2000) Marchutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation in Vitro" Biomaterials 21:1499-1507 (2000) Marchutz et al. "Oral Peptide Protein Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Pale Let al. "Investigation of Chymotrypsin Dig	(IPA)			1 ' 1
Kemmler et al. "Studies on the Conversion of Proinsulin to Insulin: 1. Conversion in Vitro with Trypsin of Carboxypeptidase B." The Journal of Biological Chemistry 246(22):6786-6791 (1971)		OSC SCVOIM MICES II MCCCCATI)		
Carboxypeptidase B" The Journal of Biological Chemistry 246(22):6786-6791 (1971) Carboxypeptidase B" The Journal of Biological Chemistry 246(22):6786-6791 (1971) Res 16:147-155 (1980) Stipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Themselven Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Themselven Control of Postprandial Plasma Glucose Levels in Pathon With Type 2 Diabetes **Mellitus** American Diabetes Association Annual Meeting (June 2001) (Poster) Kipnes et al. "The Effects of an Oral Modified Insuling on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes **Mellitus** American Diabetes Association Annual Meeting (June 201) (Abstract) Kipnes et al. "The Effects of an Oral Modified Insuling on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 201) (Abstract) Kipnes et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) Musabayane et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozoticn-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Day The Control of Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discover		TRADE MARKET	June 4, 2001 CONCURATERTLY	1654
Kipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) Extension of the Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Pathway with Type 2 Diabetes" Emerging Treatments and Technologies 26:2 (2003)	59	Carboxypeptidase B" The Journal of Biologica	al Chemistry 246(22):6786-6791 (1971)	
Type 2 Diabetes* Emerging Treatments and Technologies 26:2 (2003) Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Melitus." American Diabetes Association Annual Meeting (June 2001) (Poster) Kipnes et al. "The Effects of an Oral Modified Insuling on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 24, 2001) (Abstract) Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" Genomics and Proteomics (Sept. 2002) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin". J. Clin. Invest. 77:717-723 (1986) Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang. David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin Modified with Amphiphilic Oligomer	JR 60	Res. 16:147-155 (1980)		7
with Type 2 Diabetes Mellitus" American Diabetes Association Annual Meeting (June 2001) (Poster) 1/16. Kipnes et al. "The Effects of an Oral Modified Insuling on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 24, 2001) (Abstract) Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" Genomics and Proteomics (Sept. 2002) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Siridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery." Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Cral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer Program and Abstracts, 1999 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm.	61	Type 2 Diabetes" Emerging Treatments and Te	echnologies 26:2 (2003)	CC
with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 24, 2001) (Abstract) Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" Genomics and Proteomics (Sept. 2002) Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) 66 Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) 67 Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation in Vitro" Biomaterials 21:1499-1507 (2000) 68 Mussabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) 69 Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) 70 Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) 71 Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) 72 Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) 73 Price, IC Polyethlyene Glycol, pp. 355-361 (Nov. 1998) 74 Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) 75 Radhakrishnan et al. "Cral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1998 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) 77 Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Me	PR 62	with Type 2 Diabetes Mellitus" American Diab	oetes Association Annual Meeting (June 20	01) (Poster) //
Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986) 66 Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) 67 Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) 68 Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) 69 Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) 70 Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oilv Formulation" Pharm. Res. 7(8):852-855 (1990) 71 Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) 72 Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) 73 Price, IC Polyethlyene Glycol, pp. 355-361 (nv) Oraled) 74 Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) 75 Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery." Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) 76 Radhakrishnan et al. "Chemical Modification of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) 77 Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Ameri. Assoc. Phar	\sim 63.	with Type 2 Diabetes" American Diabetes Ass	ociation Annual Meeting (June 24, 2001) (A	Abstract)
Insulin" J. Clin. Invest. 77:717-723 (1986) Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (no) Delivery APS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	FA 64.	2002)		
Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research 9(3):357-365 (1999) 67 Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) 68 Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) 71 Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) 72 Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) 73 Price, JC Polyethlyene Glycol, pp. 355-361 (Nov. 2014) 74 Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) 75 Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) 76 Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans. LA (1999) (Abstract) 77 Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):8-59 (1998) (Abstract)	13A 65.			
Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000) Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (net delete) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	JA 66.	66 Savva & Huang "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer" Journal of Liposome Research		
Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000) Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (Nov. 2012) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):5-59 (1998) (Abstract)	PN 67			
Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)—Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991) Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (Nov. 2014) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	68	Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma		
Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990) Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (not dated) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	69	Nucci et al. "The Therapeutic Value of Poly(et		
Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998) Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) Price, JC Polyethlyene Glycol, pp. 355-361 (nvt oral oral oral oral oral oral oral oral	70	Oka et al. "Enhanced Intestinal Absorption of		Drug, Smancs, in
Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976) 73 Price, JC Polyethlyene Glycol, pp. 355-361 (not of orally Active Insulin Conjugate HIM2" 74 Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" 75 AAPS Pharm Sci. 3(3) 2001 (Abstract) 76 Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery." Proceed Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) 76 Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) 77 Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) 78 Radhakrishnan et al. "Radio Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	JRR 71	Pang, David C. "Bridging Gaps in Drug Disco	very and Development" Pharmaceutical Te	chnology 22:82-94
Price, JC Polyethlyene Glycol, pp. 355-361 (net dotted) Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	JAN 72	Patel et al. "Oral Administration of Insulin By	Encapsulation Within Liposomes" FEBS L	ett. 62(1):60-63
AAPS Pharm Sci. 3(3) 2001 (Abstract) Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	Jan 73		not dated)	
Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 25:124-125 (1998) (Abstract) Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)	J3/ 74		pigestion Profile of Orally Active Insulin Co	onjugate HIM2"
76 Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract) 77 Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) 78 Patholeichers et al. Insulin Polymertide Oligomer Conjugates Projective Polymertide Oligomer	75	Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal		
Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract) Pathologiches et al. Insulin Polymentide Oligomer Conjugates Projection Polymentide Oligomer	76	Radhakrishnan et al. "Oral Delivery of Insulin: Oligomer" Program and Abstracts, 1999 Natio	Single Selective Modification at B29-LYS	With Amphiphilic
Both almich and at al Jugulia Polymontida Oligomer Conjugates Projection Polymontida Oligomer	Ja 77	Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA		
Conjugates and Methods of Synthesizing Same, U.S. Serial No. 10/389,499, filed 03/17/2003	72/ 78	Radhakrishnan et al Insulin Polypeptide-Oligomer Conjugates, Proinsulin Polypeptide-Oligomer		

EXAMINER

DATE CONSIDERED Uniting 8, 2004 June 16, 2005
Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 9233-64CT	Serial No. 09/873,777
LIST OF DOCUMENTS CITED BY APPLICANT		·	TO BE
(Use several sheets if necessary)			TO BE ASSIGNED
	PEC 22-985 6	Applicants:	
		Ekwuribe et al.	
	A CONTRACTOR OF THE PROPERTY O	Filing Date	Group
	HAIIF	June 4, 2001 CONCURRENTLY	1654
RU 7	Aggregates" <i>Diabetes</i> 39:728-733 (1990)		
1950 8	Richards et al. "Self-Association Properties of Pharmaceutical Research 15(9):1434-1441 (19		ation Conditions"
8	Bobbins at al "Antibodies to Covolent Aggreg		abetic Patients"
82N 8	Pussell Jones C. I. "Vitamin P12 Drug Delive	ery" Proceed. Intern. Symp. Control. Rel. B	ioactive. Mater.
An 8	3 Saffran et al. "A Model for the Study of the Or 57:548-553 (1979)		4/2
FN 8	233:1081-1084 (1986)		
you 8	Sertions at al "One I Immunication of Para with Influence Virus M Protein (M1) Microspheres" Proceeds		
De 8	Shah and Shen "Transcellular Delivery of an Insulin-Transferrin Conjugate in Enterocyte-like Caco-2 Cells" Journal of Pharmaceutical Sciences 85(12):1306-1311 (1996)		like Caco-2 Cells
Ra 8	Shichiri et al. "Enteral Absorption of Water-in-Oil-in-Water Insulin Emulsions in Rabbits" Diabetologia 10:317-321 (1974)		
Jan 8	8 Soltero et al. Insulin Polypeptide-Oligomer Conjugates, Proinsulin Polypeptide-Oligomer Conjugates and Methods of Synthesizing Same U.S. Serial No. 10/382,022, filed 03/05/2003		
An 8	Colombia Di Colombia de Colomb		
132 9	O Soltero et al. Pharmaceutical Compositions of Diseases Therewith U.S. Serial No. 10/382,15:	Insulin Drug-Oligomer Conjugates and Me	ethods of Treating
972L 9	Still and McAllister "Effects of Orally Active I Pharmacol. Therap. 69(2):P95 (Feb. 2001) (A	Modified Insulin in Type 1 Diabetic Patient	s" Clinical
WILL 9	2 Still and McAllister "Effects of Orally Active I Presentation Annual Meeting of the American		
0	FL, March 9, 2001	· · · · · · · · · · · · · · · · · · ·	
gal,	3 Still and McAllister "Effects of Orally Active I of the American Society for Clinical Pharmaco		
Ju 9	Still et al. "Magnitude and Variability of Pharm	nacokinetic and Glucodynamic Responses t	o Modified Human
VA 9	Insulin Administered Orally to Healthy Volunteers" Diabetes Research and Clinical Practice 56:S77 (2002) Still et al. Methods of Reducing Hypoglycemic Episodes in the Treatment of Diabetes Mellitus, U.S. Serial		
	No. 10/461,199, filed 06/13/2003 Still, J. Gordon "Development of Oral Insulin: Progress and Current Status" Diabetes/Metabolism Research		
(A'- 	and Reviews 18(1):S29-S37 (2002)		·
My 9	7 Still, J. Gordon "Oral Insulin Development Si Diabetes 2000: Therapy and Technology, Lond		
M- 98	98. Szleifer et al. "Spontaneous Liposome Formation Induced by Grafted Poly(Ethylene Oxide) Layers: Theoretical Prediction and Experimental Verification" Proceedings of the National Academy of Sciences of the United States of America 95(3):1032-1037 (1998)		

EXAMINER *EXAMINER.

Teffrey Eilustel

DATE CONSIDERED

Tenuery 8, 2004 / June 16,2005

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Carial Na
FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 9233-64	Serial No. 29/873,77 7
Patent and Trademark Office		7230 070	TA 26
LIST OF D	DOCUMENTS CITED BY APPLICANT		ASSIGNED
,	(Use several sheets if negessary)		ASSIGNED
(Ose several sheets it heressary)	Applicants:	
	a a a a a a a a a a a a a a a a a a a	Ekwuribe et al.	
	The state of the s	Filing Date	Group
	MADEMA	Jane 4, 2001 CONCURRENTLY	1654
	Taniguchi et al. "Synthesis of Acyloyl Lysozyn	<u>l</u>	
SLI) 99.	Small Intestinal Administration in Rats" Proces	ed. Intern. Symp. Control. Rel. Bioactiv. M	ater. 19:104-105
10	(1992)		
100.	Uchio et al. "Site-Specific Insulin Conjugates v Advanced Drug Delivery Reviews 35:289-306	with Enhanced Stability and Extended Action (1999)	on Profile"
60	Mars Drofling of Synth	etic Polymers by Free-Solution Capillary F	Electrophoresis of
101.	DNA-Polymer Conjugates" Analytical Chemis	try 73(8):1795-1803 (2001)	
102.	Wahren et al. "Role of C-peptide in Human Ph (2000)	ysiology" Am. J. Physiol. Endocrinol. Met	ab. 278:E759-E768
103	Zalipsky et al. "Attachment of Drugs to Polyet	hylene Glycols" Eur. Polym. J. 19(12):117	7-1183 (1983)
104	7: and Dandeson Westing! Absorption of De		
104	Technique 49:346-352 (2000)		
•		•	7/2
	•		, Co
		<i>``</i>	The V
	·	~ C,	You The Control of th
	·	• •	CNIC TOUS
			PECEIVE CENTER 1600/2900
			00/20
			and the same of th
	•		

EXAMINER *EXAMINER Jeffry E. Russel

DATE CONSIDERED

Javey 8, 2004 June 16,200

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction

Complete if Known Substitute for form 1449B/PTO Application Number 10/806,523 March 23, 2004 Filing Date SUPPLEMENTAL Ekwuribe, Nnochiri N. First Named Inventor INFORMATION DISCLOSURE Art Unit 1654 STATEMENT BY APPLICANT Examiner Name (use as many sheets as necessary) 1 Attorney Docket Number 014811-242.64CT Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
J.	A1	MEHVAR, REZA; Modulation of the Pharmacokinetics and Pharmacodynamics of Proteins by Polyethylene Glycol Conjugation; <i>J. Pharm. Pharmaceut Sci.</i> ; 3(1):125-136; 2000	
			_
			_

Examiner Signature	Jeffrey E. Russel	Date Considered	June 16,2005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

\	□ BLACK BORDERS
	IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
	☐ FADED TEXT OR DRAWING
	☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
٠	☐ SKEWED/SLANTED IMAGES
	☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
	☐ GRAY SCALE DOCUMENTS
	☐ LINES OR MARKS ON ORIGINAL DOCUMENT
	☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
	Потивр.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.